Daily Trade News
Stock

WHO advisory panel recommends extending use of Pfizer vaccine to 5-11



© Reuters. FILE PHOTO: Doses of the Pfizer-BioNTech vaccine against the coronavirus disease (COVID-19) for children are prepared at a children doctor’s practice in Maintal near Frankfurt, Germany, December 15, 2021. REUTERS/Kai Pfaffenbach

(Reuters) – The World Health Organization’s advisory panel on Friday recommended extending the use of Pfizer (NYSE:) and German Partner BioNTech’s COVID-19 vaccine to include children aged 5 to 11 years old.

The recommendation comes after the Strategic Advisory Group of Experts (SAGE) on immunisation held a meeting on Wednesday to evaluate the companies’ vaccine. The vaccine is currently recommended for use in people aged 12 years and above.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.



Read More: WHO advisory panel recommends extending use of Pfizer vaccine to 5-11

You might also like More from author